EverSource Wealth Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

EverSource Wealth Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$28	Buy	+6	New	+$27	﹤0.01%	4486

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

EverSource Wealth Advisors's ORMP Position: Q3 2026 in Review

EverSource Wealth Advisors opened a new position in Oramed Pharmaceuticals (ORMP) in Q3 2026: 6 shares worth $28. The stake represents ﹤0.01% of the portfolio and ranks #4486 among its holdings.

40 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.

EverSource Wealth Advisors held 6 shares of Oramed Pharmaceuticals worth $28 as of Q3 2026.
Oramed Pharmaceuticals was a new EverSource Wealth Advisors position in Q3 2026.
Oramed Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q3 2026, its #4486 holding.
40 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.

Based on EverSource Wealth Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.